News items related to: Campaign action

  • Five years after the Indian Supreme Court’s Novartis verdict

    Five years after this landmark decision, the impact is being felt around the world. India’s decision is frequently held up...

  • Collective efforts by civil society groups bar the way to Hepatitis C patents

    Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position...

  • Truvada case shows civil society’s success with pre-grant opposition

    The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to...

  • Civil society key in TRIPS flexibility implementation

    Civil society plays an instrumental role in actively defending access to affordable to medicines, making use of TRIPS flexibilities, and...

  • Ukraine eyes patent law reform after civil society push on medicines access

    Ukrainian lawmakers are poised to approve sweeping patent reform legislation, driven in large part by a push by patients’ groups...

  • Fixing the broken patent system: From Marrakech and back again

    Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical...

  • Storify: Pathways to Access #GSIPA2M

    [View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave

  • GSIPA2M: The Summit Highlights

    Catch up on the activity from our inaugural Global Summit on Intellectual Property and Access to Medicines (15-17 January 2018)....

  • IP and access to medicines: welcome speech

    Our inaugural Global Summit on Intellectual Property and Access to Medicines has started today. Read Solange Baptiste’s welcoming speech below,...

  • ICASA 2017: Optimal HIV treatment for ALL

    As the 2017 International Conference on AIDS and STIs in Africa (ICASA) draws to a close in Abidja, Cote d’Ivoire,...